Urologic Cancers

UROLOGIC CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Algorithm Proposed to Expand Cisplatin Eligibility for MIBC

A new algorithm developed by Canadian investigators aims to address underuse of cisplatin-based chemotherapy for muscle-invasive bladder cancer.
ACE2 Pathway Stimulation Enhances VEGF Inhibition in ccRCC, May Help Overcome VEGF Resistance

New study data offer insight on the mechanisms of angiotensin converting enzyme 2 (ACE2) in clear cell renal cell carcinoma (ccRCC).
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends

The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
On the Radar for RCC in 2021: McGregor Discusses Combination Strategies, HIF-2α Inhibition, and Other Key Topics

Bradley McGregor, MD, clinical director of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses key topics in RCC care in 2021.
Biosimilars in Cancer Care: Insights From 2020 and Expectations for 2021

Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.

UROLOGIC CANCERS NEWS

Axitinib is an efficacious drug among patients with metastatic RCC, though selecting the appropriate

Pembrolizumab Plus Lenvatinib Prolongs Survival in Renal Cell Carcinoma

April 20, 2021

The biggest reluctance to using these stents is their cost, which is approximately six times that of their polymer counterparts. At least two studies, however, have found economic benefit when the number of stent changes the patient undergoes is considered.

Prophylactic Ureteral Stenting Linked to Upper Tract Urothelial Carcinoma

April 15, 2021

Trodelvy Gets Accelerated Approval for Urothelial Cancer

April 15, 2021

The new risk score, developed by Emory researchers, could be a useful tool for determining overall and progression-free survival after immunotherapy.

Factors Associated With Response to Nivolumab in Renal Cell Carcinoma

April 9, 2021

Surgery

Seminal Vesicle-Sparing in Radical Cystectomy Shown to Improve Outcomes

April 2, 2021

Next post in Urologic Cancers

Rates of Testicular Cancer Rising in Young Hispanic-American Men

One-Cycle BE500P Seems Safe for High-Risk Early Testicular Cancer